Effect of Idelalisib on QTc interval in healthy volunteers

Trial Profile

Effect of Idelalisib on QTc interval in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Allergic rhinitis; Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 28 Dec 2015 Results published in Blood journal.
    • 28 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top